ReviewMicroorganisms2022
Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Cutaneous Reactions after COVID-19 Vaccines: Analysis of the Clinical and Histopathological Spectrum-Case Series and Review of the Literature.Dermatopathology (Basel, Switzerland) · 2024Article
- Hyaluronidase for Dermal Filler Complications: Review of Applications and Dosage Recommendations.JMIR dermatology · 2024Review
- Oral Methotrexate Treatment of Delayed-Onset Inflammatory Reactions to Dermal Fillers.Aesthetic surgery journal. Open forum · 2024Article
- Lower Eyelid Complication After Blepharoplasty and COVID-19 Vaccination.Aesthetic plastic surgery · 2023Article
- Article
- A critical review of COVID-19 course and vaccination in dermatology patients on immunomodulatory/biologic therapy: recommendations should not differ between non-pregnant and pregnant individuals.Frontiers in medicine · 2023Review
- Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID-19 vaccine: Successful treatment with ustekinumab and acitretin.Dermatologic therapy · 2022Article
- mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks and Coverage.Acta bio-medica : Atenei Parmensis · 2022Review
- Immediate hypersensitivity to COVID-19 vaccines: Focus on biological diagnosis.Frontiers in allergy · 2022Review
- The clinical and pathologic spectrum of mucocutaneous reactions after COVID-19 vaccinations in three tertiary referral centers of northern Italy.Clinics in dermatologyArticle
- Multicentric observational study of the possible side effects of the COVID-19 vaccine in relation to absorbable thread insertion.Journal of cutaneous and aesthetic surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer-BioNTech), and AZD1222 (AstraZeneca-Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.